Metagenomi Therapeutics announced FDA clearance of its Investigational New Drug application for MGX-001, a genome editing treatment for hemophilia A. This approval allows the company to start a global Phase 1/2 trial, INTEGR8, in early 2027, aiming to provide a one-time, durable treatment by integrating the Factor VIII gene into patients' genomes. The company reported $101.7 million in cash and securities as of September 30, 2026, supporting operations into 2028. Initial clinical data on safety and efficacy are expected in the second half of 2027, potentially offering a new long-term treatment option for hemophilia A patients.
Metagenomi Therapeutics' recent FDA clearance and financial update provide context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 04:02 WIB: out of 150 priced US health stocks, 52 rose and 97 fell. Notable movers include HIMS at USD 19.05 with a -16.96% change, WGS at USD 54.79 down 16.63%, and ACAD at USD 18.36 up 11.24%.
Cannabis Strategic Ventures has finalized its change of control with Scopien Technologies, an AI platform company, which now holds voting control through preferred stock. The company has appointed new leadership, including CEO Zameer Mulla, and plans...
Star Bulk Carriers Corp. has published its 2025 Environmental, Social and Governance (ESG) Report, its eighth annual report detailing the company's sustainability strategy, performance, and future objectives. The report, guided by the ESG Committee, ...
TELA Bio reported $19 million revenue in Q3 2026, down 8% year-over-year but with an 18% increase in international sales. The company reduced its operating loss by 21% sequentially and improved adjusted EBITDA loss by 55%, driven by a strategic cost ...
Auburn National Bancorporation, Inc. announced a quarterly cash dividend of $0.27 per share, payable on December 28, 2026, to shareholders recorded by December 10, 2026. The company is the parent of AuburnBank, an Alabama state-chartered bank with ab...
OpenTable's 2027 Quebec dining trends report shows a 9% increase in restaurant bookings, with 65% of Quebecers planning to dine out as much or more in 2027. Consumers prioritize value, local favorites, and meaningful experiences, often celebrating sm...
